MedTrace Logo

Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone

NCT01263951 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2021-10-26

No results posted yet for this study

Summary

The goal of this study is to determine the effect of combining everolimus and sorafenib in patients with metastatic differentiated thyroid cancer who progressed on sorafenib alone.

Conditions

  • Differentiated Thyroid Cancer

Interventions

DRUG

Everolimus

One 5 mg. tablet daily.

DRUG

Sorafenib

200 mg. twice daily.

Sponsors & Collaborators

Principal Investigators

  • Marcia Brose, MD, PhD · Hospital of the University of Pennsylvania- Abramson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2021-02-01
Completion
2022-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01263951 on ClinicalTrials.gov